Literature DB >> 3396438

Antibiotic treatment. Aerosol therapy.

M E Hodson1.   

Abstract

Aerosol antibiotics in control studies have been shown to improve lung function and reduce the number of acute hospital admissions in patients with cystic fibrosis (CF). However, their administration is time-consuming in patients who must already take a large amount of medication daily. Aerosol antibiotics are expensive, but the cost is minimal compared with the cost of a hospital admission or intravenous antibiotics. When this method of administration of antibiotics first began to be widely used in the treatment of CF, there was much concern that hypersensitivity reactions might occur and that drug-resistant organisms would cause clinical problems. Minimal drug hypersensitivity has been reported, and there is no solid evidence that the small increase in resistance to some antibiotics associated with the use of aerosol antibiotics is in any way detrimental to the patients. These minor disadvantages must be weighed against the possible advantage of using aerosol antibiotics in any given clinical situation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396438

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Microparticles for inhalational delivery of antipseudomonal antibiotics.

Authors:  Michael D Tsifansky; Yoon Yeo; Oleg V Evgenov; Evangelia Bellas; John Benjamin; Daniel S Kohane
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

2.  Aztreonam lysine for inhalation solution in cystic fibrosis: profile report.

Authors:  Greg L Plosker
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

3.  Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection.

Authors:  Jean-Francois Marier; Jean Lavigne; Murray P Ducharme
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 4.  Aztreonam lysine for inhalation solution: in cystic fibrosis.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

5.  Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.

Authors:  C Beaulac; S Clément-Major; J Hawari; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.

Authors:  Yan Yang; Michael D Tsifansky; Chia-Jung Wu; Hae In Yang; Gudrun Schmidt; Yoon Yeo
Journal:  Pharm Res       Date:  2009-10-22       Impact factor: 4.200

Review 7.  Cystic fibrosis.

Authors:  M R Bye; J M Ewig; L M Quittell
Journal:  Lung       Date:  1994       Impact factor: 2.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.